Oxaliplatin in Treating Patients With Metastatic Breast Cancer

NCT02077998 | Completed Early Phase 1 DMC

• 4 other identifiers: UCDCC#237457404P30CA093373NCI-2013-01747
• Study Type: interventional
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients receiving carbon C 14 oxaliplatin may help doctors predict how well patients will respond to treatment with oxaliplatin. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Conditions

Stage IV Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Threshold at which oxaliplatin-DNA adducts predict response to therapy

  The concentration of oxaliplatin-DNA adducts induced will be characterized using descriptive statistics (graphical summaries, mean, standard deviation \[SD\], box plots) in PBMC and tumor for responders and non-responders to chemotherapy. The mean level of oxaliplatin-DNA adducts will be compared in responders to chemotherapy to that of non-responders using a 2-sample t-test at the 0.05 level (2-sided). The Youden index will be used to estimate and compute a 95% confidence interval for the optimal cut-point in oxaliplatin-DNA adduct levels to differentiate between responders and non-responders.

  Up to 6 months post-treatment

Secondary Outcomes (8)

• Response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST)

  Up to 6 months post-treatment

• Progression-free survival

  From the date of enrollment to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or date of death due to any cause, whichever occurs first, assessed up to 6 months post-treatment

• Overall survival

  From the first treatment to death or to the last treatment follow-up, assessed up to 6 months post-treatment

• Overall toxicity from both the carbon C 14 oxaliplatin microdose and the full dose oxaliplatin chemotherapy evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

  Up to 30 days post-treatment

• PK parameters including maximum concentration (Cmax), half-life (t1/2), and area under the curve (AUC) from both micro- and therapeutic- dosing in the same patients

  Pre-dose; 5, 15, and 30 minutes; and 2, 4, 8, 24, and 48 hours

Study Arms (1)

Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)

EXPERIMENTAL

PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1. PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Radiation: carbon C 14 oxaliplatin; Drug: oxaliplatin; Other: laboratory biomarker analysis

Interventions

carbon C 14 oxaliplatin RADIATION

Given IV

Also known as: [14C] oxaliplatin

Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)

oxaliplatin DRUG

Given IV

Also known as: 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP

Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)

laboratory biomarker analysis OTHER

Correlative studies

Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must have metastatic breast cancer that can be biopsied or resected around 48 hours after dosing with one microdose of \[14C\]oxaliplatin (carbon C 14 oxaliplatin)
• Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy
• Patients with metastatic breast cancer for which no standard therapy exists will be recruited for this study; more specifically, for patients with hormone receptor positive/human epidermal growth factor receptor 2 (Her2) negative disease, this includes previous therapy with tamoxifen or an aromatase inhibitor and one line of chemotherapy in the metastatic setting; for patients with Her2 positive disease, this includes 2 lines of Her2 directed therapy in the metastatic setting; and for patients with triple negative disease, this includes one line of chemotherapy in the metastatic setting; once we have identified the dose of \[14C\]oxaliplatin, we will only recruit triple negative breast cancer patients that progressed after one line of chemotherapy in the metastatic setting
• Any number of prior therapies other than oxaliplatin is allowed
• Eastern Cooperative Oncology Group (ECOG) performance status equal to or less than 2 (Karnofsky equal to or greater than 50%)
• Life expectancy of at least 3 months
• Absolute neutrophil count greater than or equal to 1,500/microL
• Platelets greater than or equal to 100,000/microL
• Total bilirubin less than 1.5 X institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) less than or equal to 2.5 X ULN
• Creatinine less than 1.5 X ULN
• No pre-existing sensory neuropathy \> grade 1
• Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
• Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation
• Men must agree to use adequate contraception (barrier method or abstinence) prior to study entry and for 30 days after study participation

You may not qualify if:

• Patients must not receive concomitant radiation with chemotherapy if they do not have any measurable lesions outside of the radiation field
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Participants who are pregnant or nursing
• Participants who are allergic to platinum agent
• Participants who have more than grade 1 peripheral neuropathy

Sponsors & Collaborators

• University of California, Davis: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

UC Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Oxaliplatin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals

Study Officials

• Chong-Xian Pan

  UC Davis Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2014
• First Posted: March 4, 2014
• Study Start: May 1, 2015
• Primary Completion: May 1, 2015
• Study Completion: December 1, 2015
• Last Updated: January 9, 2018

Record last verified: 2018-01

Locations

US (1)